Literature DB >> 26107189

Influence of Endosomal Escape and Degradation of α-Galactosylceramide Loaded Liposomes on CD1d Antigen Presentation.

Takashi Nakamura1, Moeka Kuroi1, Hideyoshi Harashima1.   

Abstract

Alpha-galactosylceramide (GC), a lipid antigen present on CD1d molecules, is a unique adjuvant that enables a strong antitumor effect to be induced via activation of natural killer T cells. We previously reported that a liposomal formulation of GC significantly enhanced GC presentation via CD1d and antitumor immunity. However, the influence of the intracellular fate of liposomes controlled by the lipid composition on GC presentation using GC-loaded liposomes (GC-Lip) remains unclear. In this study, we prepared a GC-Lip formulation by incorporating dioleoyl-phosphatidylethanolamine (DOPE)/cholesterol, egg phosphatidylcholine (EPC)/cholesterol, and distearoyl phosphocholine (DSPC)/cholesterol, and investigated the relationship between the intracellular trafficking of GC-Lip and GC presentation in antigen-presenting cells. When GC-Lip was prepared using DOPE, a fusogenic lipid, the endosomal escape of liposomes was enhanced, resulting in a decrease in GC presentation of CD1d, compared to the EPC based GC-Lip (EPC/GC-Lip). The stability of liposomes in endosomes/lysosomes had no influence on GC presentation. The DSPC based GC-Lip (DSPC/GC-Lip) induced GC presentation without any detectable degradation in liposomal structure, although the EPC/GC-Lip induced GC presentation with degradation of liposomal structure. The efficiency of GC presentation between EPC/GC-Lip and DSPC/GC-Lip was comparable. These GC presentations that were independent of the degradation of liposomes were dominated by saposins, sphingolipid activator proteins. Our findings reveal that GC presentation on CD1d from the fluid liposomes involves the action of saposins, regardless of whether liposome degradation occurs. This insight can be of use in terms of developing GC-Lip formulation for efficient GC presentation.

Entities:  

Keywords:  CD1d; intracellular fate of liposomes; lipid antigen presentation; liposomes

Mesh:

Substances:

Year:  2015        PMID: 26107189     DOI: 10.1021/mp500704e

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.

Authors:  Vanessa Sainz; Liane I F Moura; Carina Peres; Ana I Matos; Ana S Viana; Angela M Wagner; Julia E Vela Ramirez; Teresa S Barata; Manuela Gaspar; Steve Brocchini; Mire Zloh; Nicholas A Peppas; Ronit Satchi-Fainaro; Helena F Florindo
Journal:  Acta Biomater       Date:  2018-06-22       Impact factor: 8.947

2.  TWEAK Negatively Regulates Human Dicer.

Authors:  Marine Lambert; Geneviève Pépin; Oscar Peralta-Zaragoza; Raphaël Matusiak; Sophia Ly; Patricia Landry; Patrick Provost
Journal:  Noncoding RNA       Date:  2016-10-25

3.  Establishment of a hTfR mAb-functionalized HPPS theranostic nanoplatform.

Authors:  Qi He; Zilong Guo; Mingpeng Fu; Hongling Tang; Huifen Zhu; Guanxin Shen; Yong He; Ping Lei
Journal:  Nanotheranostics       Date:  2020-03-26

4.  MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.

Authors:  Jing-Jing Du; Shi-Hao Zhou; Zi-Ru Cheng; Wen-Bo Xu; Ru-Yan Zhang; Long-Sheng Wang; Jun Guo
Journal:  Front Chem       Date:  2022-02-04       Impact factor: 5.221

5.  Retrograde Axonal Transport of Liposomes from Peripheral Tissue to Spinal Cord and DRGs by Optimized Phospholipid and CTB Modification.

Authors:  Takafumi Fukui; Hironao Tateno; Takashi Nakamura; Yuma Yamada; Yusuke Sato; Norimasa Iwasaki; Hideyoshi Harashima; Ken Kadoya
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

6.  Designing Aptamer-Gold Nanoparticle-Loaded pH-Sensitive Liposomes Encapsulate Morin for Treating Cancer.

Authors:  Xiaoyuan Ding; Chenyang Yin; Weiwei Zhang; Yu Sun; Zhenzhen Zhang; Endong Yang; Dongdong Sun; Weiyun Wang
Journal:  Nanoscale Res Lett       Date:  2020-03-30       Impact factor: 4.703

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.